Observational studyNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026
Treatment approaches to patients with multiple sclerosis and coexisting psoriasis - A longitudinal multicenter observational cohort study.
Observational study in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurologists frequently encounter multiple sclerosis (MS) patients with coexisting autoimmune disorders such as psoriasis (PsO). The evolving landscape of immunotherapies has made treatment decisions more complex, yet also opened opportunities for therapies targeting shared immunopathogenic mechanisms. However, evidence for this patient group remains limited to case reports and small series. In this multicenter observational study, 420 MS patients were screened, identifying 38 with PsO. These were compared with MS-only patients regarding demographics, disease course, Expanded Disability Status Scale (EDSS), and disease-modifying therapy (DMT) use. DMT histories, reasons for discontinuation, and adverse events were analyzed. Logistic regression assessed PsO and MS worsening, using dimethyl fumarate (DMF) as reference. MS/PsO patients were older at diagnosis (37.6 vs. 33.0 years). EDSS and disease course showed no statistically significant differences. DMF was most frequently used (68%), with low rates of PsO (8%) and MS worsening (15%). PsO worsening was common under teriflunomide (75%), interferons (38%), and sphingosine-1-phosphate (S1P) modulators (40%). Logistic regression suggested higher odds under teriflunomide (OR = 16.5, p = 0.028), interferons (OR = 16.5, p = 0.004), and S1P-modulators (OR = 8.25, p = 0.047). Anti-CD20 therapies (OR = 2.75, p = 0.257) and natalizumab (OR = 1.83, p = 0.635) showed non-significant trends. Interleukin-17 (IL-17) inhibitors were well tolerated, with >50% stable in both conditions and no significant MS worsening (OR = 1.67, p = 0.546). IL-17 inhibitors and DMF showed a favorable tolerability in MS/PsO. Teriflunomide, interferons, and S1P-modulators frequently exacerbate PsO. CD20 therapies and natalizumab remain effective for MS but may worsen PsO; IL-17-based combinations appear promising in highly active disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.